Litcius/Paper detail

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

James M. Cleary, Emiliano Calvo, Víctor Moreno, Dejan Juric, Geoffrey I. Shapiro, Carol Ann Vanderwal, Beibei Hu, Maryella Gifford, David Barch, Lisa Roberts-Rapp, Peter Ansell, Hao Xiong, Christopher Ocampo, Anthony W. Tolcher

2020Investigational New Drugs31 citationsDOI

Topics & Concepts

MedicinePharmacokineticsEpiregulinAmphiregulinInternal medicineAntibody-drug conjugateAdverse effectEpidermal growth factor receptorPharmacologyOncologyGastroenterologyCancerAntibodyMonoclonal antibodyImmunologyHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and StudiesMonoclonal and Polyclonal Antibodies Research
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR | Litcius